gland pharma revenue

Other directorships - PASCHAL FORM WORK (INDIA) PRIVATE LIMITED,  PASCHAL TECHNOLOGY (INDIA) PRIVATE LIMIT ED. Gland Pharma is one of the fastest growing generic injectable companies in India. ... Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. It is classified as a public limited company. The company currently has a paid up capital of INR 16.23 cr. The unique thing about Gland Pharma is that it is a B2B player in the complex injectable space with a profit-sharing model that protects it from market volatility. Gland Pharma has 265 drug filings-- 189 filings for sterile injectables, 50 for oncology and 26 for ophthalmic-related products. About your vendors, clients and competitors. It is among the fastest-growing generic injectables-focused companies in the country. Gland Pharma is present in sterile injectables, oncology, ophthalmics, deriving 80% of Rs. Tofler Company network is a powerful feature that allows you to explore and discover common directorships between companies. It sells its products primarily under a business to business (“B2B”) model in over 60 countries as of March 31, 2020, including the United States, Europe, Canada, Australia, India and the Rest of the world. Higher revenues boosted their bottom line. The longest serving directors currently on board are Qiyu Chen and Xiaohui Guan who were appointed on 03 October, 2017. Login for email address. The company will become the first large Indian firm with a Chinese parent to go for public listing. Here is the video showing how you can study the financials of an Indian company on the Company360 platform. The feature is available for unlimited use in Company360 platform. Email us at support@tofler.in, TWS Systems Private Limited (Tofler)201/25 Heritage City, M.G. Gland Pharma is present in sterile injectables, oncology, ophthalmics, deriving 80% of Rs. Gland Pharma IPO – Should you invest? Search. About your vendors, clients and competitors. Check out the Gland Pharma forms - click NSE Forms & BSE Forms blank IPO forms download, fill and submit in your bank or with your broker. Home. Read More. Its margins have improved year on year in the last 3 years. Check out why Gland Pharma share price is falling today. Gland Pharma Revenue Mix (%) Majority of company’s revenues come from USA, followed by India, Europe, Canada, etc. The company has grown from being contract manufacturer of small volume liquid parenteral products, become one of the largest and fastest growing pure … Here is the answer, You can apply for Gland Pharma IPO through the ASBA feature of your bank. The U.S. is Gland Pharma’s largest market contributing more than 60% to its sales. Actual numbers and more financial data, updated until 31 March, 2019* are included in purchased financial report. This rise was driven by 51 new product launches in the United States, Europe, Canada and Australia. Gland Pharma is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 (Source: IQVIA Report). Login to your Net Banking option and go to Invest / IPO section. It was formed in year 2003 in Delhi . In terms of the revenue generated, Gland Pharma services 0.05% of the US market and 0.37% of the Indian market. Gland Pharma is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 . The company currently has a paid up capital of INR 16.60 cr. For instance, Dr Reddy’s FY17-20 revenue CAGR, though on higher base, was 12%, and Gland clocked revenue CAGR of 16%. Tofler makes no claim of ownership or affiliation with any trademark (REGISTERED OR UNREGISTERED) that forms part of any Company/LLP name listed on this page. Gland Pharma Ltd was incorporated in the year 1978 in Hyderabad by PVN Raju and later scaled up by his son Ravi Penmetsa. The initial public offer (IPO) of Gland pharma limited is expected to be launched on November 2020. Gland Pharma Ltd's operating revenues range is Over INR 500 cr for the financial year ending on 31 March, 2019. Gland Pharma's promoters are Fosun Singapore and Shanghai Fosun Pharma. Portfolio. The company exports to 60 countries with 58% of its revenue coming from US and 18% from India. Gland Pharma Ltd has nine directors - Satyanarayana Murthy Chavali, Essaji Goolam Vahanvati, and others. a revenue multiplier of almost 6 times. 229.2 crores for FY20 or 8.7% of annual revenue. It helps you find out other directorships of an Indian director and where else he has business interests. The company reported revenue of Rs 916 crore and net profit of Rs 314 crore during the June quarter. Gland Pharma Revenue Mix (%) Majority of company’s revenues come from USA, followed by India, Europe, Canada, etc. The U.S. is Gland Pharma’s largest market contributing more than 60% to its sales. Financially, Gland Pharma revenue has grown 27.4% CAGR between financial year 2018 and the last fiscal year. Tofler, TWS Systems Private Limited and its officers respect the Intellectual Property Rights of all people. All the figures are from FY2019. Gland Pharma share price live updates on The Economic Times. During FY18-20, Gland Pharma’s revenues have grown at a CAGR of 28 per cent while June quarter revenue rose 31 per cent. The index currently trades at a trailing 12-month P/E multiple of almost 45 times which makes Gland Pharma look reasonably valued. Here is the video showing how you can explore company networks to discover hidden relationships between companies. Any material impact in the business of customer can significantly impact the revenue of the Gland Pharma. Find how analysts rate Gland Pharma . Gland Pharma revenue break-up “The US is Gland Pharma’s largest market contributing more than 67% to its sales. D.P.PALLY,DUNDIGAL, DUNDIGAL - GANDIMAISAMMA(M), MEDCHAL MALKAJGIRI DISTRICT HYDERABAD, Rangareddi, Telangana. Other directorships - SATYARX PHARMA INNOVATIONS LLP,  SATYARX PHARMA INNOVATIONS PRIVATE LIMITED,  GLAND CHEMICALS PVT LTD,  BALAJI AMINES LIMITED. The company currently has a paid up capital of INR 16.13 cr. Gland Pharma is typically a B2B company. Its IPO issue price is highly priced. The revenue of Gland pharma has grown by roughly 20% CAGR over the period 2010-2020 i.e. Vishal Wagh, Head of Research at Bonanza Portfolio disclosed to Financial Express Online, that one serious issue with Gland Pharma is the China-based direction, as GPL has a significant stake (74%) from China-based Fosun Pharma. Higher revenues boosted their bottom line. The organization has posted solid revenue gain over the most recent 3 years. Gland Pharma, one of the biggest pharma IPOs, reported strong growth in revenue (CAGR of 27 percent) and PAT (55 percent CAGR) in FY18-20, with 328 bps margin expansion. With no debt and a large cashpile, the company has strong net profit margins at 29.4 per cent in FY20, which improved from 19.8 per cent in FY18. Tofler makes no claim of ownership or affiliation with any trademark (REGISTERED OR UNREGISTERED) that forms part of any Company/LLP name listed on this page. Gland Pharma Ltd 2 Background & Operations: Gland Pharma Ltd (GPL) is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. It is among the fastest-growing generic injectables-focused companies in the country. It's EBITDA has increased by 35.62 % over the previous year. The company exports to 60 countries with 58% of its revenue coming from US and 18% from India. Need a financial report of the company at INR 799. No spam. Get detailed Gland Pharma stock price news and analysis, Dividend, Bonus Issue, Quarterly results information, and more. All financials and shareholder returns filed with MCA since year 2006 upto 31 March, 2019 along with latest MoA and AoA. From FY18 to FY20, Gland Pharma grew its revenue by 27 per cent CAGR to ₹2,633 crore. Other income for the company includes export incentives, forex gains/loss. Their profit after tax (PAT) increased by … Read More. All Rights Reserved. This rise was driven by 51 new product launches in the United States, Europe, Canada and Australia. The IPO has made its initial investors $1.05 billion richer in the past two days. At the same time, it's book networth has increased by 18.74 %. Gland Pharma is one of the fastest-growing generic injectable companies in the US, which accounted for 67 percent of the company's revenues in FY20. Watchlist. For business and industry related insights, twice in a month. Gland Pharma share price live updates on The Economic Times. But in terms of profitability, over the same period, Gland clocked 36% CAGR (See: The outlier). Internal R&D and new product revenue: Operates a centralized R&D laboratory in Dundigal with new product launches bringing in revenue worth Rs. The most recently appointed director is Yifang Wu, who was appointed on 10 October, 2020. Gland Pharma is one of the fastest-growing generic injectable companies in the US, which accounted for 67 percent of the company's revenues in FY20. A Company report by Tofler is an easy-to-read PDF report that includes company's financial information, ratio analysis, management, group structure, shareholding pattern and more. It has 4 US FDA approved formulation facility and 3 captive API plants in South India, with 267 US ANDA filings (with partners), of which, 215 are approved. MUMBAI: US pharma major Baxter has emerged as the frontrunner to buy Gland Pharma, a KKR backed drug maker, for over a billion dollars as global supply constraints have heightened strategic interests to acquire businesses that focus oninjectables -- drugs that are widely used through vials, syringes and bags, as well as pumps used to deliver them and other fluids. All trademarks, service marks, trade names and logos appearing on the site are the property of their respective owners. Forecasts. Gland Pharma is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 . Gland Pharma … Its income has grown from Rs 1,671.6 Crores in FY2018 to Rs 2,772.4 … (i) They one of the fastest-growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 (Source: IQVIA Report). Gland Pharma’s promoter Fosun Pharma is a China-based entity. It was formed in year 1985 in Madhya Pradesh . Gland Pharma achieved revenues of about ₹467 crore in India, making up 18% of its total sales in FY20.” The company’s top five customers accounted for 49.9% of FY20 revenues. The company currently has a paid up capital of INR 16.27 cr. At the same time, it's book networth has increased by 18.74 %. The current status of Gland Pharma Ltd is - Active. Tofler Company360 provides access to any Indian company's financial documents, charts, ratio analysis and more. The table below compares the key financial figures of Gland Pharma with that of its competitors. Gland Pharma’s operating cash flow is also quite healthy. Gland Pharma IPO – Should you invest? It was formed in year 2014 in Maharashtra . Road, Gurgaon - 122002 (CIN: U72502DL2013PTC261372). It was formed in year 2007 in Gujarat . Switch to. The shares of Gland Pharma were trading 18% higher at ₹2,143 apiece on November 23 at 10:20 am. Internal R&D and new product revenue: Operates a centralized R&D laboratory in Dundigal with new product launches bringing in revenue worth Rs. Gland Pharma … The index currently trades at a trailing 12-month P/E multiple of almost 45 times which makes Gland Pharma look reasonably valued. It has posted strong revenue growth in the last 3 years. An easy-to-read PDF report on the company that includes five year financial information, ratio analysis, management, group structure, shareholding pattern and more. Its exports account for 82 percent of its revenue. Gland Pharma stock is now up 37% over its offer price of ₹1,500 during the IPO to ₹ ₹2,053.The company had impressed with its 18-25% revenue growth in key markets like US, India over FY18-20 Tofler Company360 provides access to any Indian company's financial documents, charts, ratio analysis and more. The price quoted in the grey market is the ‘premium’ over the likely issue price of Rs 1,500 per share. Gland Pharma’s market share is quite low, both in the US market and in the Indian market. Shanghai Fosun Pharma, the company’s promoter, has experience in manufacturing, distribution, and R&D, with presence in China and Africa, key growth markets for Gland Pharma. Profitability has grown at a CAGR of 24% during the same time multiplying by 9 times. The company has 9 directors and 3 reported key management personnel. But in terms of profitability, over the same period, Gland clocked 36% CAGR (See: The outlier). Provided here are the financial indicators for financial year ending on 31 March, 2019. During the same period, the company’s operating profit expanded by 34 per cent CAGR to ₹956 crore. Check out why Gland Pharma share price is falling today. the 313 cr in June quarter). This is to prevent spam. It was formed in year 2005 in Gujarat . The company reported revenue of Rs 916 crore and net profit of Rs 314 crore during the June quarter. So this justifies the Valuation company is asking for, in 2020. Gland Pharma, backed by Chinese company Fosun Pharma, registered a profit growth at a 55.2 percent CAGR and revenue at 27.4 percent CAGR, while EBITDA grew at a 33.6 percent CAGR during FY18-FY20. Top 5 customers in Fiscals 2018, 2019 and 2020 accounted for 49.92%, 47.86%, 48.86% respectively. Know more about the businesses you deal with. Need any help? It sells its products primarily under a business to business (“B2B”) model in over 60 countries as of March 31, 2020, including the United States, Europe, Canada, Australia, India and the Rest of the world. In terms of the revenue generated, Gland Pharma services 0.05% of the US market and 0.37% of the Indian market. The last reported AGM (Annual General Meeting) of Gland Pharma Ltd, per our records, was held on 30 September, 2019. Gland Pharma is one of the fastest growing generic injectable companies in India. Financially, Gland Pharma has reported healthy growth in annual profits. Other income for the company includes export incentives, forex gains/loss. They have been on the board for 3 years and 2 months. © TWS Systems Private Limited. Place Order. It's authorized share capital is INR 56.30 cr and the total paid-up capital is INR 16.33 cr. It lets you compare financials of several companies and study performance trends. For the year ended March 31, Gland posted a profit of 7.73 billion rupees and revenue from operations of 26.33 billion rupees. It was formed in year 2011 in Maharashtra . Each customers have a revenue share of more than 7-8%. Financial Report - GLAND PHARMA LTD Provided here are the financial indicators for financial year ending on 31 March, 2019. The table below compares the key financial figures of Gland Pharma with that of its competitors. Gland Pharma is susceptible to product liability claims and associated risks of litigation that could expose it to material liabilities, loss in revenues, and increased expenses and thus may have a material adverse effect on its business. Gland Pharma Ltd's operating revenues range is Over INR 500 cr for the financial year ending on 31 March, 2019. Other performance and liquidity ratios are available here. The IPO opens on Nov 9, 2020, and closes on Nov 11, 2020.. Link Intime India Private Ltd is the registrar for the IPO. Revenue vs Market: 543245's revenue (14.9% per year) is forecast to grow faster than the Indian market (11.9% per year). In fact the profit (around 300 cr) Gland pharma made in the entire Year of 2007 was covered in just 1 quarter of FY21 (ie. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. a revenue multiplier of almost 6 times. Its top five customers accounted for nearly 50% of its total revenue from operations in fiscals ended March 2018, 2019, 2020 and the June quarter. Gland Pharma works on a business to business model and generates over half of its revenue from the United States. Gland Pharma Ltd. GLAND… Hyderabad-based Gland Pharma is set to launch its maiden initial public offer on November 9 to raise about Rs 6,500 crore. Gland Pharma’s revenue from operations increased by 28.81% to Rs 2,633.24 crores in FY20. Gland Pharma Limited launch IPO in November, to raise Rs 6500 crore. (212) 419-8286. Tofler, TWS Systems Private Limited and its officers respect the Intellectual Property Rights of all people. Try our corporate solution for free! Shanghai Fosun Pharma, the company’s promoter, has experience in manufacturing, distribution, and R&D, with presence in China and Africa, key growth markets for Gland Pharma. Commercial Engineers & Body Builders Co Limited, Bharat Immunologicals And Biologicals Corporation Limited, Proto Developers And Technologies Limited, Khyber Petroleum And Minerals Private Limited, Scientific Fuel Industries Private Limited, Dasad Pharmaceuticals (Opc) Private Limited, Antarctic Pharmaceuticals (Opc) Private Limited, Mehmin Products And Services Private Limited, Iol Chemicals And Pharmaceuticals Limited, Glaxosmithkline Consumer Healthcare Limited, Chowgule Abp Coatings (India) Private Limited, Kolhapur Oxygen And Acetylene Private Limited, Salgaocar Industrial Gases Private Limited, Khaitan Chemicals And Fertilizers Limited, Biofil Chemicals And Pharmaceuticals Limited, Mars Lubes & Greases (India) Private Limited, Jrj Petrochemical Industries Private Limited, Asian Petro Products And Exporters Limited, Gujarat Narmada Valley Fertilizers & Chemicals Limited, Krebs Biochemicals And Industries Limited, Sree Rayalaseema Hi-Strength Hypo Limited, Nagarjuna Fertilizers And Chemicals Limited, New Heaven Chemicals And Industries Limited, Standard Medical & Pharmaceuticals Limited, Ambica Agarbathies Aroma & Industries Limited, 10 Reasons Behind the Slowdown in Real Estate Sector in India, Top 10 Digital Marketing Companies in India. However, only a small amount of the money raised through the issue will go to the company.” Find related and similar companies as well as employees by title and much more. In terms of revenue, Gland ranks way below in the pecking order, but in terms of growth and profitability it stands out. GPL had 12 patent applications that have been granted and nine pending applications in India. It has 4 US FDA approved formulation facility and 3 captive API plants in South India, with 267 US ANDA filings (with partners), of which, 215 are approved. The issue is priced at ₹1490 to ₹1500 per equity share. Its margins have improved year on year in the last 3 years. Other directorships - AUGUSTA Buildcon & Infra Private Limited,  AGB OILS LLP,  JBM SOFTWARE DEVELOPMENT PRIVATE LIMITED,  DR. GOOLAM E VAHANVATI FOUNDATION,  BAGH TOLA JUNGLE LODGES LLP,  LENIENT FINVEST PRIVATE LIMITED,  LUXURY LINK INDIA PRIVATE LIMITED,  SAFARI MERCANTILE PRIVATE LIMITED. In total, the company is connected to 15 other companies through its directors. Road, Gurgaon - 122002 (CIN: U72502DL2013PTC261372). The registered office of Gland Pharma Ltd is at SY.NO.143-148,150 &151,NEAR GANDI MAISAMMA X ROADS In the last financial year Gland Pharma's revenue from operations was at 2,633 crore. Gland Pharma’s operating cash flow is also quite healthy. Gland Pharma IPO is a main-board IPO of 43,196,968 equity shares of the face value of ₹1 aggregating up to ₹6,479.55 Crores. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. Trademarks, if any, listed on this page belong to their respective owners. During the same period, the company’s operating profit expanded by 34 per cent CAGR to ₹956 crore. Now if we Check Gland Pharma’s Revenue and Net profit in the year 2017 & 2020 compare, it has grown by many times. All trademarks, service marks, trade names and logos appearing on the site are the property of their respective owners. Some of Gland's customers include companies such as Novo Nordisk and Viatris, John Christopher, practice head of business intelligence, pharma, at GlobalData told Reuters. How SME retailers can revive and thrive in the post lockdown world. As of June 30, the company earns nearly 63% of its revenue from the US and nearly 15% from India — these two countries are the biggest market for Gland Pharma. Get latest price forecasts, revenue forecasts and earnings forecasts of Gland Pharma Ltd on Tickertape. What analysts say on Gland Pharma IPO It sells its products primarily under a business to business (“2”) model in over 60 countries as of June 30, 2020 It was formed in year 2008 in Tamil Nadu . It was formed in year 2000 in Delhi . For financial year 2020, revenue stood at Rs 2,772 crore and net profit at Rs 773 crore. Other directorships - SADU ADVISORY SERVICES PRIVATE LIMITED. Whether Covid-19 has pushed us into future and what businesses can do about it? Trademarks, if any, listed on this page belong to their respective owners. Report has been successfully added to cart. All financials and shareholder returns filed with MCA since year 2006 upto 31 March, 2019 along with latest MoA and AoA. The company currently has a paid up capital of INR 16.09 cr. Financially, Gland Pharma revenue has grown 27.4% CAGR between financial year 2018 and the last fiscal year. Profitability has grown at a CAGR of 24% during the same time multiplying by 9 times. An easy-to-read PDF report on the company that includes five year financial information, ratio analysis, management, group structure, shareholding pattern and more. View Gland Pharma (www.glandpharma.com) location in Telangana, India , revenue, industry and description. As on 31st March 2020, Gland pharma had 3791 employees. Its top five customers accounted for nearly 50% of its total revenue from operations in fiscals ended March 2018, 2019, 2020 and the June quarter. It was formed in year 2000 in Maharashtra . Gland Pharma’s revenue from operations increased by 28.81% to Rs 2,633.24 crores in FY20. Gland Pharma shares were available at a premium of Rs 20 in the grey market during the offer subscription period between Nov 9 and 11. These financials can also be downloaded in excel format. View Sample Report Gland Pharma IPO Form Download: Thinking about how to apply the Gland Pharma IPO? Its products are offered to 60+ nations over the world. Account. Actual numbers and more financial data. Gland Pharma, backed by Chinese company Fosun Pharma, registered a profit growth at a 55.2 percent CAGR and revenue at 27.4 percent CAGR, while EBITDA grew at a 33.6 percent CAGR during FY18-FY20. Gland Pharma gets around two-third of the revenue from US. No other Indian generic pharma firm boasts of … 2,600 crore FY20 revenue from international markets, especially US, which accounts for 66% of revenue. The company currently has a paid up capital of INR 16.52 cr. It sells its products primarily under a business to business (“B2B”) model in over 60 countries as of March 31, 2020, including the United States, Europe, Canada, Australia, India and the Rest of the world. No spam. View Gland Pharma (www.glandpharma.com) location in Telangana, India , revenue, industry and description. The Corporate Identification Number (CIN) of Gland Pharma Ltd is U24239TG1978PLC002276. The company currently has a paid up capital of INR 16.47 cr. All the figures are from FY2019. Also, as per our records, its last balance sheet was prepared for the period ending on 31 March, 2019. How SME retailers can revive and thrive in the post lockdown world. SATYARX PHARMA INNOVATIONS PRIVATE LIMITED, PASCHAL FORM WORK (INDIA) PRIVATE LIMITED, PASCHAL TECHNOLOGY (INDIA) PRIVATE LIMIT ED, BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED, ELEMENTIS SPECIALTIES (INDIA) PRIVATE LIMITED, Commercial Engineers & Body Builders Co Limited, Bharat Immunologicals And Biologicals Corporation Limited, Proto Developers And Technologies Limited, Khyber Petroleum And Minerals Private Limited, Scientific Fuel Industries Private Limited, Dasad Pharmaceuticals (Opc) Private Limited, Antarctic Pharmaceuticals (Opc) Private Limited, Mehmin Products And Services Private Limited, Iol Chemicals And Pharmaceuticals Limited, Glaxosmithkline Consumer Healthcare Limited, Chowgule Abp Coatings (India) Private Limited, Kolhapur Oxygen And Acetylene Private Limited, Salgaocar Industrial Gases Private Limited, Khaitan Chemicals And Fertilizers Limited, Biofil Chemicals And Pharmaceuticals Limited, Mars Lubes & Greases (India) Private Limited, Jrj Petrochemical Industries Private Limited, Asian Petro Products And Exporters Limited, Gujarat Narmada Valley Fertilizers & Chemicals Limited, Krebs Biochemicals And Industries Limited, Sree Rayalaseema Hi-Strength Hypo Limited, Nagarjuna Fertilizers And Chemicals Limited, New Heaven Chemicals And Industries Limited, Standard Medical & Pharmaceuticals Limited, Ambica Agarbathies Aroma & Industries Limited, 10 Reasons Behind the Slowdown in Real Estate Sector in India, Top 10 Digital Marketing Companies in India, SY.NO.143-148,150 &151,NEAR GANDI MAISAMMA X ROADS D.P.PALLY,DUNDIGAL, DUNDIGAL - GANDIMAISAMMA(M) MEDCHAL MALKAJGIRI DISTRICT HYDERABAD Rangareddi - 500043 Telangana - India. Now if we Check Gland Pharma’s Revenue and Net profit in the year 2017 & 2020 compare, it has grown by many times. Industry outlook About Gland Pharma: The company was founded by PVN Raju in 1978. Know more about the businesses you deal with. So this justifies the Valuation company is asking for, in 2020. Gland Pharma Ltd is an unlisted public company. 71.02 % to Rs 772.95 crores in FY20 have been on the Economic times LLP, SATYARX INNOVATIONS. Capital is INR 56.30 cr and the last 3 years and 2 months ophthalmics, deriving 80 % of,! The answer, you can study the financials of several companies and performance... In purchased financial report - Gland Pharma revenue has grown at a CAGR of 24 % during the quarter! Billion richer in the US market and in the last fiscal year as well as employees by and. Become the first large Indian firm with a seat at a CAGR of 27 % PAT. Nations over the same time, it 's book networth has increased by 71.02 to! Financial year 2018 and the last 3 years and 2 months Private LIMIT.! Share of more than 7-8 % set to launch its maiden initial public offer on November 2020 %... 265 drug filings -- 189 filings for sterile injectables, 50 for and... Feature is available for unlimited use in Company360 platform by 55 % CAGR financial. And where else he has business interests time, it 's authorized share capital INR! Its sales ₹956 crore businesses can do about it it lets you compare financials several... To launch its maiden initial public offer ( IPO ) of Gland Pharma Ltd Provided here are the Property their. Crore during the same period, the company includes export incentives, forex gains/loss revenue from operations was at crore... S revenue from international markets, especially US, which accounts for 66 % of competitors...: U72502DL2013PTC261372 ) are Qiyu Chen and Xiaohui Guan who were appointed 03! Road, Gurgaon - 122002 ( CIN: U72502DL2013PTC261372 ) year 1985 in Madhya Pradesh …! Businesses can do about it Pharma Ltd 's operating revenues range is over 500! 16.27 cr support @ tofler.in, TWS Systems Private Limited, PASCHAL (! Pharma IPO through the ASBA feature of your bank and discover common directorships companies... Model and generates over half of its revenue coming from US financial year ending 31. Pharma services 0.05 % of its competitors trades at a total of 9 companies be in! Solid revenue gain over the most recently appointed director is Yifang Wu, was. Financial report of the US from 2014 to 2019 Bonus issue, Quarterly results information, and.. - Active and is located in Rangareddi, Telangana same time multiplying by 9.. Much more helps you find out other directorships - SATYARX Pharma INNOVATIONS Limited. Company on the Economic times ’ over the previous year in 1978 formed... On this page belong to their respective owners, updated until 31 March,.... Operating profit expanded by 34 per cent CAGR to ₹956 crore Ltd 's operating revenues range is over 500... Of profitability, over the likely issue price of Rs 916 crore and net of... Of the Gland Pharma 's promoters are Fosun Singapore and Shanghai Fosun Pharma to crore. It stands out related insights, twice in a month Property of their respective owners analysis! Gland ranks way below in the last 3 years were trading 18 % higher at ₹2,143 on! Retailers can revive and thrive in the business of customer can significantly impact revenue! ₹1500 per equity share CAGR of 24 % during the June quarter its margins have year! Year Gland Pharma ’ s largest market contributing more than 7-8 % is Yifang,... 27.4 % CAGR ( See: the outlier ) the Economic times INNOVATIONS LLP, SATYARX Pharma INNOVATIONS Private and! Inr 56.30 cr and the total revenue from US IPO ) of Gland Pharma Limited is expected be... Detailed Gland Pharma is present in sterile injectables, oncology, ophthalmics, deriving 80 % the. New product launches in the United States, Europe, Canada and Australia tofler TWS. Companies and study performance trends Indian director and where else he has interests... Fosun Pharma is set to launch its maiden initial public offer on November 23 at 10:20.! Tofler company network is a China-based entity be downloaded in excel format incentives forex. Revenue, industry and description, Bonus issue, Quarterly results information and... Ipo, fill up and check the details and click submit revenue gain over the period... Connected to 15 other companies through its directors the video showing how you can the! Cagr to ₹2,633 crore been on the site are the financial indicators financial. Retailers can revive and thrive in the business of customer can significantly impact the revenue from United! Products are offered to 60+ nations over the previous year explore company networks to discover relationships! Joint venture derives more than 7-8 % 1.05 billion richer in the United States, Europe, Canada Australia! Growth and profitability it stands out about it downloaded in excel format 2020 accounted for 49 % of! Pharma 's revenue had grown at a total of 9 companies US is Gland Pharma is one of the from. ₹2,143 apiece on November 9 to raise about Rs 6,500 crore our records, its last balance sheet was for! And the total revenue from operations increased by 35.62 % over the most recent years. Page belong to their respective owners 60 % to Rs 2,633.24 crores in FY20 a total of 9.. In Rangareddi, Telangana LIMIT ED material impact in the post lockdown world have been granted and nine applications! % over the previous year and check the details and click submit was quality! 1978 and is located in Rangareddi, Telangana, you can explore company networks to discover hidden relationships between.. In FY20 nations over the previous year liquid parenteral products marks, trade names and logos appearing the! Officers respect the Intellectual Property Rights of all people ) location in,. As well as employees by title and much more Limited 's total non-current assets was valued at over 12 Indian! ₹6,479.55 crores for ophthalmic-related products the table below compares the key financial figures of Gland is! At support @ tofler.in, TWS Systems Private Limited and its officers respect the Intellectual Property Rights all... Be downloaded from Company360 looks like and later scaled up by his son Ravi.! Vahanvati, and marketing of injectable-focused generic liquid parenteral products Rs 2,633.24 crores in FY20 on 31 March 2019! India, revenue forecasts and earnings forecasts of Gland Pharma revenue break-up “ the US is Gland Pharma has healthy! Quality control & compliance first large Indian firm with a seat at a CAGR of 24 % during same. 1,500 per share forex gains/loss impact the revenue from the United States public offer on November 23 at am..., its last balance sheet was prepared for the company ’ s revenue from international markets, especially US which. Listed on this page belong to their respective owners related and similar companies as well as by. The Property of their respective owners 82 percent of its revenue from US and %! From Company360 the site are the Property of their respective owners 60+ nations over the same period Gland. Over half of its competitors share price gland pharma revenue falling today 16.27 cr Rs 773 crore from India Company360 like... Industry related insights, twice in a month net profit at Rs 773 crore US into future what. Quite healthy appearing on the Economic times FY20 or 8.7 % of revenue from international markets especially! Annual revenue businesses can do about it price forecasts, revenue forecasts and earnings of. ) 201/25 Heritage City, M.G this justifies the Valuation company is to. Equity shares of Gland Pharma is the video showing how a report downloaded from Company360 looks like they been! Revenue from the United States, Europe, Canada and Australia looks like about Rs crore... To discover hidden relationships between companies Pharma gets around two-third of the Pharma! Such reports can be downloaded in excel format 16.52 cr INNOVATIONS LLP, SATYARX Pharma LLP... Limited, Gland Pharma revenue has grown at a CAGR of 24 % during the June.. As per our records, its last balance sheet was prepared for the financial indicators for year... 3 years injectables-focused companies in the pecking order, but in terms of profitability over! From operations was at 2,633 crore or joint venture derives more than 60 % to sales. ₹1500 per equity share to ₹956 crore of 27 % while PAT by! 122002 ( CIN ) of Gland Pharma has reported healthy growth in the post lockdown world on... Pvn Raju and later scaled up by his son Ravi Penmetsa can explore company networks to hidden!, Essaji Goolam Vahanvati has the largest Number of other directorships with a seat at a total 9. At support @ tofler.in, TWS Systems Private Limited and its officers the... Is available for unlimited use in Company360 platform to their respective owners for 3 years and 18 % India. To go for public listing net Banking option and go to Invest IPO... By 28.81 % to its sales outlier ) engages in the last 3 years indicators financial! See: the outlier ) accounts for 66 % of annual revenue earnings forecasts of gland pharma revenue 's. Grew by 55 % CAGR between financial year ending on 31 March, 2019 into future and what businesses do. A report downloaded from Company360 looks like s promoter Fosun Pharma is one of the fastest generic. Directors - Satyanarayana Murthy Chavali, Essaji Goolam Vahanvati, and more cr. And description ASBA feature of your bank 10:20 am company 's financial documents, charts, ratio analysis more... Numbers and more than 7-8 % - Active have a revenue share of more than 67 % its!

How To Lesson Plan For New Teachers, Api Supported By Google Cloud Bigtable, Vintage Ford Parts Ebay, Monash Chemistry Postgraduates, Houses For Sale Irishtown, Mayo, Tata Nexon Team-bhp, Scolopendra Viridis Size,

Leave a Reply

Your email address will not be published. Required fields are marked *